Heron Therapeutics, Inc. (HRTX)

Market Cap	166.76M -46.7%
Revenue (ttm)	150.71M +1.5%
Net Income	-30.94M
EPS	-0.18
Shares Out	189.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	540,748
Open	0.8730
Previous Close	0.8919
Day's Range	0.8700 - 0.8900
52-Week Range	0.7362 - 2.3000
Beta	1.71
Analysts	Strong Buy
Price Target	3.67 (+316.57%)
Earnings Date	May 11, 2026

About HRTX

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 1987
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: HRTX
• Website: https://www.herontx.com

Financial Performance

In 2025, Heron Therapeutics's revenue was $154.90 million, an increase of 7.36% compared to the previous year's $144.29 million. Losses were -$20.20 million, 48.7% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price target is $3.67, which is an increase of 316.57% from the latest price.

Price Target

$3.67

(316.57% upside)

Analyst Consensus: Strong Buy